Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF

Autor:	Javed Butler, P van der Meer, Iain C. Macdougall, Sandra Waechter, Ewa A. Jankowska, Dimitrios Farmakis, Gerasimos Filippatos, Frank Ruschitzka, M. Metra, Bridget-Anne Kirwan, Vincent Fabien, Piotr Ponikowski, Stefan D. Anker
Rok vydání:	2021
Předmět:	medicine.medical_specialty business.industry Internal medicine Heart failure Medicine In patient Subgroup analysis Iron deficiency Cardiology and Cardiovascular Medicine business medicine.disease Gastroenterology FERRIC CARBOXYMALTOSE
Zdroj:	Web of Science
ISSN:	1522-9645 0195-668X
DOI:	10.1093/eurheartj/ehab724.1053
Popis:	Background Iron deficiency is associated with increased morbidity and mortality in patients with acute heart failure (HF), even in the absence of anaemia. Purpose This prespecified subanalysis of the AFFIRM-AHF trial investigated the effects of ferric carboxymaltose (FCM) on recurrent HF hospitalisations and cardiovascular (CV) mortality in patients with and without anaemia defined as baseline haemoglobin (Hb) Methods In total, 1108 patients (558 FCM, 550 placebo) were included in the modified intention-to-treat AFFIRM-AHF analysis. The primary outcome was a composite of total HF hospitalisations and CV death, evaluated up to 52 weeks post-randomisation. Results Of the 1108 patients, 228 and 329 in the FCM group and 236 and 314 in the placebo group had Hb Conclusion Iron deficiency treatment with FCM following acute HF reduced the risk of HF hospitalisations and CV death, irrespective of Hb level at baseline. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Vifor Pharma Ltd. Figure 1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc92e2ee97df92d52aaf27dc12519ad4 https://doi.org/10.1093/eurheartj/ehab724.1053 Zobrazit plný text záznamu